Tag: Lambert-Eaton Myasthenic Syndrome (LEMS)
FDA Approves FirdapseĀ® (Amifampridine) For The Treatment Of Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Nov. 29, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved FirdapseĀ® (amifampridine) 10 mg tablets for the treatment […]